title: MUC2 protein expression status is useful in assessing the effects of             hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon             cancer.
abstract: We conducted a molecular biological investigation to determine the outcomes             of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment, and whether it             is effective in all cases for patients with peritoneal dissemination of colon             cancer. In the HIPEC group, the 3-year survival rate was 39.2%, whereas in the             non-HIPEC group the 3-year survival rate was 15.6%. MUC2 expression was investigated             in the HIPEC group, in patients positive for MUC2 expression, and the 3-year survival             rate was 0.0%, while in patients negative for MUC2 expression, the 3-year survival             rate was 61.1%. In addition, as a result of introducing MUC2-siRNA into a colon             cancer cell line with high expression of the MUC2 gene, the cell death rate from             heat and anticancer agents increased 40% in comparison with colon cancer cells             in which scrambled siRNA had not been introduced. HIPEC therapy is thought to             be effective in prolonging survival in patients with peritoneal dissemination             of colon cancer, and MUC2 expression is thought to be useful as an indicator to             assess its effectiveness in colon cancer cells.
authors.affiliation: First Department of Surgery, University of Fukui, 23-3 Eiheiji-cho,                     Yoshida-gun, Fukui, Japan.
authors.forename: Yuka
authors.initials: Y
authors.lastname: Fujishima
authors.forename: Takanori
authors.initials: T
authors.lastname: Goi
authors.forename: Youhei
authors.initials: Y
authors.lastname: Kimura
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Hirono
authors.forename: Kanji
authors.initials: K
authors.lastname: Katayama
authors.forename: Akio
authors.initials: A
authors.lastname: Yamaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D045744:Cell Line, Tumor; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008297:Male; D008875:Middle Aged; D055262:Mucin-2 / Q000096:biosynthesis* / Q000235:genetics; D010534:Peritoneal Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000235:genetics; D014162:Transfection
chemical_list: C524625:MUC2 protein, human; D055262:Mucin-2; D012333:RNA, Messenger; D034741:RNA, Small Interfering